ALZ Talks: Alzheimer’s Treatment Update
Join us for an update on lecanemab, the anti-amyloid treatment just approved by the FDA. Alzheimer’s Association Chief Public Policy Officer Robert Egge and Senior Director of Medical Scientific Relations, Dr. Claire Sexton, will review additional details about the drug, how it is administered, and potential side effects and benefits. The conversation will also address next steps around access to the treatment.
February 8, 2023 I 12 p.m. CDT